Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$6.55 USD
-0.44 (-6.29%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.60 +0.05 (0.76%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Income Statements
Fiscal Year end for Emergent Biosolutions Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,049 | 1,121 | 1,793 | 1,555 | 1,106 |
Cost Of Goods | 705 | 694 | 758 | 524 | 434 |
Gross Profit | 344 | 427 | 1,035 | 1,031 | 673 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,070 | 600 | 683 | 598 | 558 |
Income After Depreciation & Amortization | -726 | -173 | 353 | 434 | 114 |
Non-Operating Income | 83 | -12 | -4 | 5 | 2 |
Interest Expense | 88 | 37 | 35 | 31 | 38 |
Pretax Income | -731 | -222 | 314 | 407 | 77 |
Income Taxes | 29 | 2 | 84 | 102 | 23 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -761 | -224 | 231 | 305 | 55 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -761 | -224 | 231 | 305 | 55 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -362 | -25 | 481 | 552 | 228 |
Depreciation & Amortization (Cash Flow) | 365 | 147 | 128 | 118 | 114 |
Income After Depreciation & Amortization | -726 | -173 | 353 | 434 | 114 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 51.20 | 50.10 | 54.10 | 53.80 | 52.40 |
Diluted EPS Before Non-Recurring Items | -6.23 | -2.23 | 6.02 | 7.88 | 2.91 |
Diluted Net EPS (GAAP) | -14.85 | -4.47 | 4.27 | 5.67 | 1.04 |
Fiscal Year end for Emergent Biosolutions Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 254.70 | 300.40 | 275.80 | 270.50 | 337.90 |
Cost Of Goods | 296.10 | 144.60 | 182.90 | 176.80 | 190.60 |
Gross Profit | -41.40 | 155.80 | 92.90 | 93.70 | 147.30 |
SG&A, R&D, and Dept/Amort Expenses | 162.10 | 116.00 | 136.20 | 335.80 | 440.20 |
Income After SG&A, R&D, and Dept/Amort Expenses | -203.50 | 39.80 | -43.30 | -242.10 | -292.90 |
Non-Operating Income | -42.70 | -3.40 | 11.00 | -4.10 | 71.30 |
Interest Expense | 23.60 | 24.30 | 21.70 | 19.70 | 28.60 |
Pretax Income | -269.80 | 12.10 | -54.00 | -265.90 | -250.20 |
Income Taxes | 13.30 | 3.10 | -1.20 | -2.50 | 11.10 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -283.10 | 9.00 | -52.80 | -263.40 | -261.30 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -283.10 | 9.00 | -52.80 | -263.40 | -261.30 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 52.60 | 52.20 | 51.90 | 51.80 | 50.70 |
Diluted EPS Before Non-Recurring Items | -2.32 | 0.59 | -0.77 | -1.44 | -1.06 |
Diluted Net EPS (GAAP) | -5.38 | 0.17 | -0.97 | -5.08 | -5.15 |